BREAST CANCER

Results from a new study could lead to the development of biomarkers for predicting treatment response and the implementation of strategies to address acquired resistance of CDK4/6 inhibitors in HR-positive/HER2-negative breast cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Tiffany A. Traina, MD, reviewed data from the TROPiCS-02 and DESTINY-Breast04 and discussed using antibody-drug conjugates in patients with metastatic breast cancer.

Closing out their program on HR+/HER2- metastatic breast cancer, panelists look toward future evolutions in the treatment landscape.

In the second article of a 2-part series, Aditya Bardia, MD, MPH, leads a discussion on the practice-changing use of sacituzumab govitecan and trastuzumab deruxtecan for patients with advanced breast cancer.

Key opinion leaders on breast cancer management share insight on the evolving role of antibody drug conjugates and their potential impact on care.

Following her review of TROPiCS-02, Joyce O’Shaughnessy, MD, shares data from the DESTINY-Breast04 study of T-DXd in HER2-low metastatic breast cancer.

Fertility preservation should be offered to anyone who is interested in becoming pregnant after chemotherapy for breast cancer.

Expert Joyce O’Shaughnessy, MD, reviews data from the TROPiCS-02 study of sacituzumab govitecan in HR+/HER2- metastatic breast cancer.

Expert perspectives on a second patient case of unmutated metastatic breast cancer and available treatment strategies in this setting.

Sara Tolaney, MD, MPH, discusses key takeaways from the TROPiCS-02 study of sacituzumab govitecan-hziy for patients with hormone receptor-positive/HER2-negative metastatic breast cancer, and highlights other trials evaluating the agent.

Expert panelists consider how they might apply data from the EMERALD study in their real-world management of HR+/HER2- metastatic breast cancer.

A focused review of data from the EMERALD study, which tested elacestrant, an oral SERD, in patients with HR+/HER2- metastatic breast cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Aditya Bardia, MD, MPH, discussed treatment approaches for a patient with hormone receptor–positive, HER2- negative metastatic breast cancer?

In the second article of a 2-part series, Joyce O’Shaughnessy, MD, discusses the most recent findings from the phase 3 EMERALD study for patients with hormone receptor–positive metastatic breast cancer.

In the first article of a 2-part series, Aditya Bardia, MD, MPH, leads a discussion on what factors influence sequencing treatment for patients with estrogen receptor positive advanced breast cancer.

In light of the second-line treatment armamentarium for patients with HR+/HER2- metastatic breast cancer, expert oncologists discuss the selection and sequencing of specific agents in this setting.

Joyce O’Shaughnessy, MD, highlights key data from a number of clinical trials in the second-line treatment setting of HR+/HER2- metastatic breast cancer.

A number of trials evaluating rintatolimod as a combinational therapy for a wide range of solid tumor types are underway and planned, including in pancreatic and breast cancer.

According to Erica Mayer, MD, MPH, an analysis of the PALLAS study that patients with a higher BMI appeared to have less toxicity from the CDK4/6 inhibitor, palbociclib, and fewer cases of early discontinuation due to toxicity.

An era of advanced molecular testing and personalized medicine has allowed for the de-escalation of breast cancer treatment for many patients. This is part 1 of a 2-part series on overtreatment of breast cancer.

In this first part of a 2-article series, Joyce O’Shaughnessy, MD, recent updates to treatment and testing guidelines for patients with advanced breast cancer whose disease harbors an ESR1 mutation.

Docetaxel with carboplatin, trastuzumab, and pertuzumab has led to improved overall survival in patients with HER2-positive metastatic breast cancer. These findings led to the evaluation of dual blockade therapy in the neoadjuvant and adjuvant settings.

KEYNOTE-756 is the first positive phase 3 study to generate a statistically significant improvement in pathological complete response rate with an immunotherapy regimen in the neoadjuvant setting for ER-positive/HER2-negative breast cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Elizabeth Mittendorf, MD, discussed how antibody-drug conjugates fit into the treatment algorithm for patients with advanced breast cancers.

In an interview with Targeted Oncology, Hope S. Rugo, MD, explained the results of the phase 3 CAPItello-291 trial, and the potential impact of the study on the breast cancer treatment paradigm.